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Background: Periprocedural myocardial injury (PPMI) during percutaneous coronary interventions (PCI) is increased in patients (pt) with type II 
diabetes mellitus (T2DM). The long-term risk of ischemic heart events has been related to the extent of cardiac troponin I (cTnI) after PCI. Aim of the 
study was to assess the influence of Pioglitazone (Pio) pretreatment on PPMI in diabetics.
Methods: A prospective double-blinded trial was conducted in 5 centers, including 95 pt. with T2DM scheduled for elective PCI. They were 
randomized to either placebo or Pio (30 mg/day for 1 week, followed by 45 mg/day for 2 weeks added to their previous medication). The primary 
efficacy variable was PPMI incidence, defined as cTnI elevation >1 ULN 24h after stent-PCI. Secondary efficacy variables were endothelial oxidative 
stress parameters up to 1 week after PCI.
Results: Full data sets were available in 77 pt. (Pio: 40, placebo: 37) with successful uncomplicated PCI. cTnI >1 ULN was found in 20/40 pt. 
(50%) after treatment with Pio, compared to 12/37 pt. on placebo (32.4 %). No demografic, clinical, or procedural data predicted PPMI. Significant 
differences between treatment groups were observed only for adiponectin and E-selectin (Table).
Conclusions: The changes in adiponectin and E-selectin showed that a 3-week pretreatment with Pio reduced inflammatory response and 
microvascular permeability, but not PPMI, which might be more related to plaque composition than to routinely assessed clinical and laboratory 
data.
 
